New collaboration to deliver personalised oncology treatment
16 Oct 2015 by Evoluted New Media
AstraZeneca and the University of Manchester have announced a collaboration aiming to deliver personalised healthcare for cancer patients.
AstraZeneca and the University of Manchester have announced a collaboration aiming to deliver personalised healthcare for cancer patients.
It will focus on clinical bioinformatics research that will develop real-time data system for better identification of the right cancer treatment. As part of the five-year agreement, AstraZeneca will invest £11.5 million to support the research led by the recently established Centre for Cancer Biomarker Sciences at the Manchester Cancer Research Centre.
“This collaboration is exciting because it will eventually allow us to incorporate important data from clinical trials into a format that can be reviewed in real time by healthcare professionals and matched with information about cancer medicines. We will be able to modify clinical trial programmes accordingly and support clinicians to offer more accurate, personalised and rapid decision making to patients about their treatment,” said AstraZenica’s Executive Vice President of Innovative Medicines & Early Development, Mene Pangalos.
The research will focus on the development of a new bioinformatics system which will secure and incorporate clinical trial safety, efficacy, biomarker, more personalised healthcare and drug distribution data in real time by presenting information that can easily be interpreted by clinicians.
Professor Andrew Hughes from the Institute of Cancer Sciences said: “Patient insight is key to our understanding of new cancer drugs. The information we get from patients about their experiences of taking new drugs is key to shaping our risk: benefit assessment. AstraZeneca has long supported the UK science base and this latest collaboration with the Manchester Cancer Research Centre will enable the patients to share their insights with investigators and sponsors more effectively and efficiently than today – enabling a more informed assessment.”
The collaboration will also support new training programmes in clinical research and pharmacokinetic and pharmacodynamic modelling aiming to help scientists understand the distribution and clinical effects of medicines within the body.
